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Summary 
Developmental activation of VDJ recombination at the T  cell receptor (TCR) 8 locus is con- 
trolled by an intronic transcriptional enhancer (Es). Transcriptional activation by E~ is depen- 
dent on c-Myb. To determine whether c-Myb plays a role in the activation of TCR-8 gene 
rearrangement, we compared VDJ recombination in transgenic mice carrying two versions of a 
human TCR-8 gene minilocus recombination substrate. One includes a wild-type Es, whereas 
the other carries an E 8 with a mutation that abrogates c-Myb binding. We demonstrate that an 
intact Myb binding site is necessary for efficient rearrangement of the minilocus substrate, sug- 
gesting that  c-Myb plays a  crucial  role  in  activating VDJ  recombination  at  the  endogenous 
TCR-8 locus. 
T 
he protein c-Myb plays important roles in the differ- 
entiation  and  proliferation  of hematopoietic  cells  (1, 
2).  Gene-targeted c-myb-homozygous mutant mice die in 
utero  and  display severe  anemia  and  other  defects in  he- 
matopoiesis by fetal day  14.5  (3).  Further,  T  cell-specific 
overexpression of dominant-negative  myb alleles  in  trans- 
genic mice results in impaired T  cell proliferation and dif- 
ferentiation (4). However, because inhibition of Myb func- 
tion has pleiotropic effects, specific roles for Myb proteins 
in vivo have remained elusive. Myb proteins activate tran- 
scription  by  specific  binding  to  the  nucleotide  sequence 
PyAACT/GG (1,  2).  Yet only a few genes that are specifi- 
cally  expressed  in  hematopoietic  cells  are  known  to  be 
Myb targets (5-10). We have previously shown in transient 
transfection experiments that TCR-8 gene transcription  is 
regulated by the T  lineage-specific TCR-8 enhancer (Es) 1 
(11),  and that the binding of c-Myb to the 8E3 element of 
E 8 is essential for enhancer activity (7). 
The regulated activation of VDJ recombination at TCR 
and Ig gene loci is an essential feature of lymphoid cell de- 
velopment  (12,  13).  VDJ  recombination  has  been  corre- 
lated  with  germline  transcription,  suggesting  a  link  be- 
tween  the  two  processes  (14-18).  Direct  evidence  that 
transcriptional promoters and enhancers  can regulate VDJ 
recombination  in  developing  lymphocytes  has  been  ob- 
tained from studies of transgenic mice that carry recombi- 
nation substrates (19-24)  and from studies that use homol- 
tAbbreviations used in this paper: CAT, chloramphenicol acetyl transferase; 
Es,  TCR-8  enhancer; EsmMyb, E8 with a TCR-8 enhancer with a 
Myb-binding site mutation; 1.4E~BS, 1.4-kb wild-type E  8 subcloned into 
the XbaI site ofpBluescript KS+; E-, enhancerless. 
ogous recombination to eliminate regulatory elements from 
endogenous loci (25-27). 
We have previously studied VDJ recombination in trans- 
genic mice carrying an unrearranged human TCR-B gene 
minilocus  (22,  23).  This construct  includes  germline V~I, 
V82, DB3, Jal, J83, and Ca segments, as well as the TCR-8 
enhancer  (Es) within  the J83-C8  intron.  Frameshift muta- 
tions  in  the  V  segments  prevent  the  expression  of func- 
tional TCR chains such that the transgene serves as a neu- 
tral reporter of  VDJ recombination. We found that transgene 
rearrangement is T  cell specific and occurs stepwise, first V 
to D  and then VD to J. Notably, in most lines of transgenic 
mice carrying a minilocus with E8 deleted, the initial V  to 
D  step still occurs, but the subsequent VD-to-J step is dra- 
matically inhibited.  This result suggests that E 8 is required 
for J  segment accessibility, but is not required for V  or D 
segment accessibility. This system therefore offers the  op- 
portunity to test the role of.specific cis-acting enhancer se- 
quences in regulating VDJ recombination. In this study, we 
specifically address the role of Myb proteins in the recom- 
binational enhancer activity of Es. 
Materials and Methods 
Production of Transgenic Mice.  E8 with a Myb-binding site mu- 
tation  (E~mMyb) was generated by PCR. using as a template the 
1.4-kb  wild-type Ea subcloned  into the XbaI site of pBluescript 
KS+  (1.4EBBS). Mutagenic  oligonucleotides  MybPCRup  and 
MybPCRdn that include  a 2-bp change in the BE3 element and 
generate a HindllI site were described (7). Linearized plasmid was 
subjected to PCR in two different reactions including either oli- 
gonucleotides  MybPCRup  and  EsPCR  (AAGGTTTAATTC- 
289  j. Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/96/01/289/05  $2.00 
Volume 183, January 1996 289-293 AGTCAGAC) or MybPCR.dn and the  reverse  primer.  The  5' 
550-bp  fragment was  digested  with  HindlII  and  PflMI,  the  3' 
290-bp fragment was digested  with HindlII and BamHI, and the 
two  were  ligated  together  into  PflMI-  and  BamHI-digested 
1.4EBBS. The insert was sequenced to confirm its structure,  after 
which  the  1.4-kb EsmMyb was  excised  with Xba[ and  cloned 
into XbaI-digested, phosphatase-treated pBluescript  carrying the 
enhancerless  minilocus  (22). Minilocus  DNA was  purified  and 
microinjected into fertilized C57BL/6 ￿  SJL F2 eggs as described 
previously (22). Transgenes were maintained  on a mixed C57BL/6 
￿  SJL background. 
PCR.  The  preparation  of genomic  DNA,  conditions  for 
PCR.,  probes  for  Southern  blot  analysis,  and  quantification  of 
PCR  signals were  as  described  (22). The  amount  of template 
DNA used  for PCR. reactions  was  12  ng for single-copy inte- 
grants.  Template quantity was  reduced for multicopy integrants 
to account for copy number and to keep all PCR. signals in the 
linear  range.  Reported VD and VDJ rearrangement signals were 
normalized to the C~ signal for each DNA sample. 
Transfection and Chloramphenicol  Acetyl Transferase (CA T) Assays. 
Enhancers were cloned upstream of the V81 promoter in XbaI- 
digested  and phosphatase-treated Val-CAT  (11). The human T 
cell line Jurkat was transfected,  and CAT assays were performed 
as described  (7, 11). 
Results 
A 2-bp mutation within the 8E3 element ofa 370-bp E~ 
fragment  eliminates  in  vitro  binding  of c-Myb  and  abro- 
gates  transcriptional  activation  (7).  The  same  2-bp  muta- 
tion was introduced into the 1.4-kb E~ fragment previously 
shown  to  regulate  transgene  rearrangement  to  generate 
E8mMyb  (Fig.  1 A).  We first examined  the  effect of the 
Myb binding site mutation on E8 transcriptional activity by 
subcloning E8  and EsmMyb  into  the  enhancer-dependent 
test  construct  V~I-CAT,  and  assaying  CAT  activity  after 
transient transfection of the constructs into Jurkat ceils  (Fig. 
2).  E8 was active in both orientations  (38.7- and 34.8-fold 
induction),  whereas  EamMyb  was  completely  inactive 
(0.5- and 0.2-fold induction).  Thus, an intact Myb binding 
site within 8E3 is essential for the transcriptional  activity of 
the  1.4-kb E8 as assayed by transient transfection. 
E~mMyb  was  then  substituted  for  the  wild-type  E~ 
within the transgenic minilocus  (Fig.  1 A), and three inde- 
pendent  lines  of transgenic  mice  carrying the  mutant  en- 
hancer were established.  Minilocus rearrangements in three 
transgenic  lines  carrying wild-type E a  (A,  B,  and  C)  (22) 
were compared with those in the three transgenic lines car- 
tying EsmMyb  (P,  Q,  and 1K). Ea lines  A, B,  and  C  each 
carry  a  single  copy  of the  minilocus  (22).  Among  the 
EamMyb lines, P carries three copies, Q  carries four copies, 
and IK carries 15 copies. To assess transgene rearrangement, 
thymocyte  genomic  DNA  templates  were  analyzed  by 
quantitative  PCR, and specific PCR products were identi- 
fied by hybridization with radiolabeled V81 and Va2 cDNA 
probes  (Fig.  1  B).  The  primer  combinations  V~l-J~l  and 
V82-Ja1  can amplify a  product of 0.3  kb  that  reflects VDJ 
rearrangement  and  one  of 1.2  kb  that  reflects  VD  rear- 
rangement  (22).  The  primer  combinations  Val-J83  and 
A  Constructs: 
vd  V~2  D63 J61 363  C6 
.....---  E0 ,4k  
...~ 
,...--'""  Core  Myb  ",,, 
i  i  I  3 
wild-type  ATGCATGTGGTTTCCAACCGTTAATGCT 
mutant  ATGCATGTGGTrrCCAAGCTTrAATGCT 
L  a 
6E3 
B  v  d  rearrangements: 
Chromosome  PCR product 
V61  1363 J61  383 
;,,/~t  I  I  I  germline  none 
=~.  -"  I  V61-D6  3  1.2kb 
; ~'-----I-  V61-D6  3-J~1  0.3 kb 
~11-  V61-0  6 3-J  6 3  0.3 kb 
Figure  1.  Human TC1K-8 gene minilocus. (A) Filled boxes represent 
exons, open boxes represent protein-binding sites within Es,  and  se- 
quences of wild-type and mutant 8E3 elements are shown. (B) V81 rear- 
rangement products generated using V81, J8l,  and J~3 primers are de- 
picted. Arrows denote PC1K primers. A similar set of V82 rearrangement 
products are generated using V82, J8l, and J83 primers. No products are 
amplified from unrearranged templates. 
V~2-J~3 amplify only a 0,3-kb product that reflects VDJ re- 
arrangement  (Fig.  1  B).  Amplification was  also performed 
using a pair of C8 primers  as an internal  control.  Of note, 
E8 line  C  carries  a  truncated  minilocus  that lacks  the V81 
gene  segment,  limiting  the  analysis  to Va2  rearrangements 
in this line (22). 
Consistent  with  previous  experiments  (22),  VDJ  rear- 
ranged products were readily detectable with all four primer 
combinations  in  E8  lines  A  and  B,  and  with  V82  and J~ 
primers in E~ line C  (Fig. 3 A). Furthermore,  as assessed  us- 
ing  the  primer  combinations  V8l-Jal  and  v~2-j81,  VDJ- 
Figure  2.  Transcriptional activation by wild-type E  8 and  E6mMyb. 
The  indicated enhancers were tested in both  orientations (arrows) up- 
stream of the V81  promoter in the  enhancer-dependent test construct 
V81-CAT. Jurkat cells were transfected in duplicate, and values for per- 
cent chloramphenicol acetylation were averaged and then normalized to 
the activity of the E- V81-CAT construct. 
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ranged products in each case, indicating that the enhancer- 
dependent  VD-to-J  step  of  transgene  rearrangement  is 
highly efficient. Remarkably, the EamMyb lines displayed a 
very different phenotype.  In all three lines and with every 
primer  combination,  the  absolute  amount  of VDJ  rear- 
rangement  was  dramatically inhibited.  Relative  to  E 8 line 
A, the levels of V81-D83-J81  rearrangement in the E~mMyb 
lines were 0.1% in P  (i.e.,  [0.036/25.618]  ￿  100), 0.2% in 
Q, and 5.4% in R, and the levels of V81-DB3-J~3 rearrange- 
ment  were  0.1%  in  line  P,  0.1%  in  Q,  and  1.5%  in  R 
(Table  1).  Levels of V82 rearrangements were similarly di- 
minished.  Furthermore,  in  all three  lines,  VD-rearranged 
products were  more abundant than VDJ-rearranged prod- 
ucts,  indicating  that  the  VD-to-J  step  of transgene  rear- 
rangement was preferentially inhibited. Some inhibition of 
the V-to-D step of rearrangement was nevertheless appar- 
ent, most notably in line P. Similar conclusions were drawn 
from analysis of a second individual in each of the EsmMyb- 
transgenic lines (Fig. 3  B). 
Table 1.  Quantification  of Minilocus Rearrangement 
Ea  EamMyb 
A  B  C  P  Q  R 
Val-Da3  4.491  4.423  nd  0.322  2.391  6.194 
V81-Da3-Js1  25.618  5.255  nd  0.036  0.059  1.388 
V81-D~3-J~3  14.110  1.452  nd  0.015  0.011  0.215 
V82-D83  0.051  0.060  0.012  nd  0.045  0.427 
V82-Da3-J~1  2.297  0.261  1.219  nd  0.007  0.026 
V82-D83-J~3  0.419  0.064  0.260  nd  nd  0.016 
Hybridization signals from the PCR experiment presented in Fig. 3 A 
were quantified using a Betascope (Betagen, Waltham,  MA). The re- 
ported VD and VDJ rearrangement signals were normalized to the Ca 
signal for each DNA sample, nd, not detectable. 
Figure 3.  Minilocus rearrangement an- 
alyzed by PCR. (A) Genomic DNA from 
thymi of wild-type E  8 mice from lines  A, 
B, and C, and from EamMyb mice from 
lines  P,  Q,  and  R  were  amplified by 
quantitative  PCR  using  the  indicated 
primers, and Southern blots were  devel- 
oped  using  radiolabeled  Val  or  Va2 
cDNA probes. A pair of Ca primers and a 
radiolabeled C  a probe  served as internal 
controls. The mice analyzed  were A584 (3 
wk  old), B31  (8  wk  old),  Cl14  (4 wk 
old), P13 (4 wk old), Q29 (2 wk old), and 
R18 (4 wk old). (B) Analysis  of additional 
EsmMyb mice P34 (8 wk old), Q60 (5 wk 
old), and R41  (6 wk old). Ea mice were 
identical to those in A. 
We  also  analyzed  minilocus  rearrangement  directly by 
genomic  Southern blot  (Fig. 4).  Unlike the  PCR  experi- 
ments,  in which DNA  samples were adjusted to normalize 
for copy number before analysis, in this experiment similar 
quantities ofgenomic DNA were analyzed. In accord with 
the  PCR  data,  thymus  DNA  from  E8  line A  displayed a 
low level of V81-D83  rearrangement  (0.9  kb),  and higher 
levels of Val-Da3-J81  and V81-D83-J83  rearrangement (1.7 
and  3.2  kb,  respectively). This  rearrangement  profile was 
dramatically perturbed in EsmMyb lines P, Q, and R. Re- 
arrangement was undetectable in line P. Line Q  displayed a 
high  level  of VD  rearrangement  but  no  VDJ  rearrange- 
ment,  whereas  line R  displayed a  high  level of VD  rear- 
rangement  and  a  very  low  level  of VDJ  rearrangement. 
Notably, VDJ  rearrangement in line R  was just barely de- 
tected by genomic Southern blot despite a  15-fold increase 
in transgene copy number relative to E8 line A. The South- 
Figure 4.  Minilocus Vs1 rearrangement analyzed  by genomic Southern 
blot. PstI plus EcoRI-digested tail (germline control) and thymus DNA 
samples (7 p~g) from lines  A, P, Q, and R were electrophoresed through 
1% agarose and blotted onto  a nylon membrane. The blot was probed 
with a radiolabeled 1.0-kb Vs1 genomic PstI fragment (22). Mice A584, 
P13, Q29, and R18 are analyzed. 
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of PCR. 
The quantitative differences among EsmMyb lines could 
result from differences in the  properties  of transgene inte- 
gration  sites,  differences  in  transgene  copy  number,  or 
both.  Importantly,  the  range  of phenotypes  displayed  by 
the EsmMyb-transgenic lines is very similar to the range of 
phenotypes  displayed by lines  of transgenic  mice carrying 
distinct integrations of an enhancerless (E-) minilocus (22). 
We  conclude  that  the  EsmMyb  minilocus  is  functionally 
equivalent  to an E-  minilocus,  and  that  disruption  of the 
8E3 Myb-binding site essentially eliminates the ability of E8 
to activate VDJ recombination. 
Discussion 
c-Myb clearly has pleiotropic effects on cell proliferation 
and differentiation within multiple  hematopoietic lineages. 
It has  therefore  been  difficult  to  obtain  information  from 
either gene-targeting or dominant negative approaches that 
would implicate c-Myb in the regulation of specific molec- 
ular events.  As an alternative,  we chose to disrupt  a func- 
tional  Myb-binding  site  within  a  phenotypically  neutral 
VDJ recombination  reporter  construct in transgenic  mice. 
This approach has the clear advantage over the gene-target- 
ing and dominant-negative approaches in that any defect in 
VDJ recombination must be a direct effect of the mutation, 
rather than an indirect effect that is secondary to a develop- 
mental perturbation.  Using this strategy, we found that ef- 
ficient VDJ recombination of a TCR-8 gene reporter con- 
struct  requires  an intact  Myb-binding site  within  the  8E3 
element of E 8. 
Our data argue strongly that a member of the Myb fam- 
ily plays a crucial role in activating TCR-8 gene rearrange- 
ment. However, the disruption of a cis-acting element can- 
not  by itself formally  implicate  c-Myb.  Nevertheless,  we 
have previously shown that c-Myb can bind to the 8E3 site 
in vitro  and  can transactivate  gene expression  in vivo  (7). 
Furthermore, the activation of TCR-8 gene rearrangement 
correlates closely with the apparent onset of c-Myb expres- 
sion in developing hematopoietic cells,  c-Myb is known to 
be expressed at highest levels in immature thymocytes (28), 
and the defect in hematopoiesis in c-Myb knockout mice is 
first apparent  at  day  14.5  of fetal  development  (3).  In ac- 
cord with this, VDJ recombination at the endogenous mu- 
rine TCR-8 locus occurs in the immature CD3-CD4-CD8- 
population  of postnatal  thymocytes and  is  initiated  at  day 
14.5  of fetal  development  (29,  30),  and  the  enhancer- 
dependent VD-to-J step of transgenic minilocus rearrange- 
ment is activated in the same population of postnatal  thy- 
mocytes and at the same stage of  fetal thymocyte development 
(23).  Given  all  of the  available  data,  we  conclude  that 
c-Myb plays a  direct  role in the  developmental  activation 
of VDJ recombination at the TCR-8 locus. 
It is generally accepted that  enhancers regulate VDJ  re- 
combination  by  modulating  the  accessibility  of chromo- 
somal  substrates  to  the  recombinase  (12).  However,  the 
mechanism by which accessibility is regulated is poorly un- 
derstood.  Although  VDJ  recombination  correlates  with 
germline transcription (14-18), a causal relationship has not 
been established  (24, 31, 32).  Our results implicate a tran- 
scription factor that is known to be important for TCR-8 
gene transcription as an important regulator of VDJ recom- 
bination. Although consistent with the correlation between 
transcription  and rearrangement,  our results do not neces- 
sarily  argue  that  transcription  is  causal  in  activating  VDJ 
recombination.  Enhancers  can  affect  local  chromatin  ac- 
cessibility,  even in the  absence of detectable  transcription 
(33, 34). Thus, the binding ofc-Myb to EB could play a di- 
rect  role  in  modulating  TCR-8  locus  accessibility  to  the 
recombinase that is at least  in part distinct  from its  role in 
transcription.  Additional studies are clearly necessary to re- 
solve this issue. 
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